Saphnelo (Anifrolumab-fnia) for Lupus | MyLupusTeam

Connect with others who understand.

sign up Log in
About MyLupusTeam
Powered By

Saphnelo is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe systemic lupus erythematosus (SLE), or lupus, who are receiving other lupus medications. Saphnelo is also referred to by its drug name, anifrolumab-fnia.

Saphnelo is a type of biologic treatment known as a type 1 interferon receptor antagonist. Saphnelo is believed to work by dampening immune system signaling that can cause inflammation.

How do I take it?
Prescribing information states that Saphnelo is administered as an intravenous infusion every four weeks. Saphnelo is administered in a medical office.

Side effects
The FDA-approved label for Saphnelo lists common side effects including the common cold, upper respiratory infections, bronchitis, cough, shingles, and infusion-related reactions such as headache, nausea, and fatigue.

Rare but serious side effects listed for Saphnelo include serious infection and serious allergic reaction.

For more details about this treatment, visit:

Saphnelo — AstraZeneca

What You Need To Know About Saphnelo — Lupus Foundation of America

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in